PT  - JOURNAL ARTICLE
AU  - Yu Hu
AU  - Hayley Dingerdissen
AU  - Samir Gupta
AU  - Robel Kahsay
AU  - Vijay Shanker
AU  - Quan Wan
AU  - Cheng Yan
AU  - Raja Mazumder
TI  - Identification of Key Differentially Expressed MicroRNAs in Cancer Patients Through Pan-cancer Analysis
AID  - 10.1101/388892
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 388892
4099  - http://biorxiv.org/content/early/2018/08/09/388892.short
4100  - http://biorxiv.org/content/early/2018/08/09/388892.full
AB  - A number of microRNAs (miRNAs) functioning in gene silencing have been associated with cancer progression. However, common expression patterns of abnormally expressed miRNAs and their potential roles in multiple cancer types have not yet been evaluated. To minimize the difference of patients, we collected miRNA sequencing data of 575 patients with tumor and adjacent non-tumorous tissues from 14 cancer types from The Cancer Genome Atlas (TCGA), and performed differential expression analysis using DESeq2 and edgeR. The results showed that cancer types can be grouped based on the distribution of miRNAs with different expression patterns. We found 81 significantly differentially expressed miRNAs (SDEmiRNAs) unique to one of the 14 cancers may affect patient survival rate, and 21 key SDEmiRNAs (nine overexpressed and 12 under-expressed) associated with at least eight cancers and enriched in more than 60% of patients per cancer, including four newly identified SDEmiRNAs (hsa-mir-4746, hsa-mir-3648, hsa-mir-3687, and hsa-mir-1269a). The downstream effect of these 21 SDEmiRNAs on cellular functions was evaluated through enrichment and pathway analysis of 7,186 protein-coding gene targets from literature mining with known differential expression profiles in cancers. It enables identification of their functional similarity in cell proliferation control across a wide range of cancers and to build common regulatory networks over cancer-related pathways. This is validated by construction of a regulatory network in PI3K pathway. This study provides evidence of the value of further analysis on SDEmiRNAs as potential biomarkers and therapeutic targets for cancer diagnosis and treatment.